Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=23 Viral Therapy in Treating Patients With Metastatic Melanoma
Recurrent Melanoma · Stage IV Melanoma
Primary: Tumor Response — 0; 0 participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=64 Ipilimumab + Temozolomide in Metastatic Melanoma
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=158 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 2 N=58 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Phase 2 N=102 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Metastatic Melanoma · Skin Cancer
Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants
Phase 2 N=32 Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Melanoma · Skin Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 18.8 Percentage of participants
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=26 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Melanoma (Skin)
Primary: Clinical Tumor Regression — 1; 1; 9; 2 Participants
Phase 2 N=8 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Liver Metastases · Lung Metastases · Recurrent Melanoma
Primary: Rate of Progression-free Survival by mWHO Criteria — 0.75 months
Phase 2 N=33 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P — 0; 2; 0; 0 Participants
Phase 2 N=80 Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Phase 2 N=49 Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Phase 2 N=149 Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Melanoma (Skin)
Primary: Progression-free Survival — 5.6; 5.1 months
Phase 2 N=16 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
Phase 3 N=129 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Metastatic · Uveal Melanoma
Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…
Phase 3 N=3,219 A Study of Vemurafenib in Participants With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Phase 2 N=7 CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: CTL With Anti-CTLA4
Phase 2 N=10 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Skin Cancer · Metastatic Melanoma
Primary: Response — 0; 0; 8; 2 Participants